latest news releases from the newsroom
Volvo Construction Equipment Sells Compact Motor Grader Product Line to Current Management
GOTEBORG, Sweden, July 07, 2004 (PRIMEZONE) -- Volvo Construction Equipment (Volvo CE) has sold its compact motor grader business to Champion LLC, Charlotte, North Carolina, a company organized by Gary Abernathy, manager of the Volvo compact motor grader product line since 1997. Abernathy became of manager of the business in 1993 under its previous owner, Champion Road Machinery, Ltd., which was acquired by Volvo CE in 1997.
Randgold Resources Limited
Randgold Resources Consolidating in Tanzania
LONDON, July 7, 2004 (PRIMEZONE) -- London and Nasdaq listed gold miner Randgold Resources (LSE:RRS) (Nasdaq:GOLD) announced today that it had consolidated and extended its exploration presence in the Lake Victoria goldfields of Tanzania through a joint venture agreement with Barrick.
Landshypotek: The district heating group credits
STOCKHOLM, Sweden, July 7, 2004 (PRIMEZONE) -- The process of exiting the lending exposure of Lantbrukskredit, a subsidiary of Landshypotek, to the district heating group has today moved forward as Lantbrukskredit has entered into an agreement with the owners of the group.
Telelogic Signs 735,000 Agreement with European Bookmaking Organization
MALMO, Sweden, July 7, 2004 (PRIMEZONE) -- Telelogic (Stockholm Exchange:TLOG), the leading global provider of solutions for advanced systems and software development, today announced that it has signed a contract worth 735,000 with a major European bookmaking organization for Telelogic's change and configuration management solution SYNERGY. The contract includes licensing fees and three year maintenance to a value of 515,000 and professional services to a value of 220,000.
Xenova Group PLC
TransMID -- First Patient Treated in Pivotal Phase III GBM Trial
SLOUGH, U.K., July 7, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that patient dosing has begun in the Phase III clinical trial of TransMID(TM) for the treatment of progressive or recurrent non-operable Glioblastoma Multiforme (GBM). The first patient was enrolled at University of Utah Huntsman Cancer Institute in the US. On 11 May 2004, Xenova and the FDA reached agreement under the Special Protocol Assessment procedure for the revised Phase III clinical trial programme for TransMID(TM).